Cost of rimegepant and lasmiditan associated adverse events, for acute treatment in migraine in Spain.

OBJECTIVE

To compare the cost of adverse events (AEs) associated with the acute treatment with rimegepant (RIM) versus lasmiditan (LAS) for migraine in Spain.

METHODS

A probabilistic modeling analysis was performed, using second-order Monte Carlo simulations, from the perspective of the Spanish National Health System (SNHS). The cost per patient of all AEs described with RIM or LAS in 12 clinical trials, obtained through a systematic review, was analyzed. Several sensitivity analyzes (among them, a matching adjusted indirect comparison -MAIC- of the two long-term studies) were also performed. The cost of AEs management (€ 2024) was obtained from Spanish sources.

RESULTS

The probabilistic model estimated that RIM compared to LAS would generate savings of €612.79 (95% CI €159.49-1339.43) per treated patient with migraine, in a treatment period of 6.11 ± 3.25 months, €98.54 per month. In the MAIC analysis, a saving per patient of €697.04 (95% CI: €514.44-879.04) was obtained in a treatment period of 12.4 months. The probability of RIM saving in all analysis was 100%.

CONCLUSIONS

In accordance with this model, the favorable safety profile of RIM compared to LAS would generate savings for the SNHS in health-care resources in all the scenarios considered.